In Actavis, the Supreme Court held that reverse payment settlements may be subject to antitrust scrutiny. The Supreme Court noted that "the plaintiff agreed to pay the defendants many millions of dollars to stay out of its market" which it found to be "unusual," and could act as a proxy for a potential antitrust violation. 6 Thus, a large payment flowing from the brand to generic may fall within Actavis 's ambit.